<DOC>
	<DOCNO>NCT00003624</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . PURPOSE : Phase II trial study effectiveness amifostine reduce risk side effect cause cisplatin paclitaxel treat woman ovarian , peritoneal , cervical , fallopian tube , uterine , endometrial cancer .</brief_summary>
	<brief_title>Amifostine Treating Women With Ovarian , Peritoneal , Cervical , Fallopian Tube , Uterine , Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy amifostine reduce significant peripheral neuropathy woman ovarian , peritoneal , cervical , fallopian tube , uterine , endometrial cancer treat cisplatin paclitaxel . II . Determine proportion patient regimen experience significant peripheral neuropathy 3 month complete chemotherapy . III . Assess overall toxicity regimen patient . OUTLINE : Patients receive paclitaxel IV 3 hour , amifostine IV 10 minute , cisplatin IV 90 minute . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Neurotoxicity assess vibration perception threshold test perform prior course chemotherapy 3 month follow last treatment . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 29-59 patient accrue study within 18-36 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Ovarian , primary peritoneal , cervical , fallopian tube carcinoma , uterine sarcoma , endometrial adenocarcinoma propose treatment cisplatin plus paclitaxel Must ineligible high priority GOG protocol PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 03 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST alkaline phosphatase great 3 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No hypertension medication discontinue 24 hour day chemotherapy treatment Other : No history neuropathy ( e.g. , diabetic neuropathy ) No significant infection Prior malignancy allow disease free least 12 month No physical disability preclude vibration perception threshold test upper low extremity ( e.g. , amputation , paraplegia ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy ovarian , primary peritoneal , fallopian tube carcinoma , uterine sarcoma , endometrial adenocarcinoma Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy except cervical carcinoma Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage I cervical cancer</keyword>
	<keyword>stage II cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IV cervical cancer</keyword>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage I endometrial carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>stage I uterine sarcoma</keyword>
	<keyword>stage II uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>neurotoxicity</keyword>
</DOC>